

Heterocyclic Studies. Part XXXIV.¹ Some 5*H*-Pyrimido[4,5-*b*][1,4]thiazine-6(7*H*)-ones, -4,6(3*H*,7*H*)-diones and -2,4,6(1*H*,3*H*,7*H*)-triones

By **Jim Clark** * and **Ian W. Southon**, Department of Chemistry and Applied Chemistry, University of Salford, Salford M5 4WT

Condensation of several 6-substituted 5-aminopyrimidine-4(3*H*)-thiones (1: X= Cl, OEt, SH, or OMe) with chloroacetic acid and of the methoxy-compound with various α -bromo-esters gave corresponding 4-substituted 5*H*-pyrimido[4,5-*b*][1,4]thiazine-6(7*H*)-ones. The 4,6(3*H*,7*H*)-diones were made by acidic hydrolysis of the corresponding 4-methoxy-6(7*H*)-ones. Alkylation before or both before and after hydrolysis furnished 5- or 3,5-dialkyl derivatives of the diones. 3-Methyl- and 1,3-dimethyl-5*H*-pyrimido[4,5-*b*][1,4]thiazine-2,4,6(1*H*,3*H*,7*H*)-trione were made from the appropriate pyrimidinethiones and chloroacetic acid.

IN Part XXXII² we described the synthesis of some 4-(substituted amino)-5*H*-pyrimido[4,5-*b*][1,4]thiazine-6(7*H*)-ones as potential pharmaceutical agents. The work has now been extended to include several more

thiazinones together with some diones and triones and certain alkyl derivatives of these compounds.

¹ Part XXXIII, J. Clark and M. S. Morton, preceding paper.

² J. Clark and I. W. Southon, *J.C.S. Perkin I*, 1974, 1805.

(a) 4-Substituted 5*H*-Pyrimido[4,5-*b*][1,4]thiazin-6(7*H*)-ones.—Treatment of 4-chloro-6-ethoxy-5-nitropyrimidine with sodium hydrogen sulphide gave the amino-ethoxy-thione (1; X = OEt). This and its known chloro-, methoxy-, and mercapto-analogues (1; X = Cl, OMe, or SH) were condensed with chloroacetic acid to yield pyrimidothiazinones (2; R¹ = R² = R³ = H, X = OEt, Cl, OMe, or SH) (Table 1). The last compound was produced by treatment of the thione (1; X = SH) with only 1 mol. equiv. of chloroacetic acid; treatment with an excess of chloroacetic

5*H*-6(7*H*)-ones (2). The fact that the u.v. spectra of the 7,7-dimethyl and 7-unsubstituted compounds are almost identical, for both neutral molecules and anions, confirmed that the compounds exist in the 7*H*-tautomeric form in aqueous solution whether ionised or not (for u.v. spectra see Experimental section).

(b) 5*H*-Pyrimido[4,5-*b*][1,4]thiazine-4,6(3*H*,7*H*)-diones.—The foregoing 4-methoxy-5*H*-pyrimidothiazin-6(7*H*)-ones, two of which had been prepared previously,^{4a} were converted into the corresponding 5*H*-pyrimidothiazine-4,6(3*H*,7*H*)-diones (3; R³ = R⁴ = H)

TABLE 1
5*H*-Pyrimido[4,5-*b*][1,4]thiazin-6(7*H*)-ones

Compound (2)				Method of prepn.*	Yield (%)	Cryst. solvent	M.p. (°C)	Formula	Found (%)			Required (%)		
X	R ¹	R ²	R ³						C	H	N	C	H	N
OEt	H	H	H	(a)	36		198—200	C ₈ H ₉ N ₃ O ₂ S	44.8	4.3	19.7	44.5	4.3	19.9
Cl	H	H	H	(a)	17		157	C ₆ H ₄ ClN ₃ OS	34.7	2.3	20.5	35.7	2.0	20.8
							(decomp.)							
SH	H	H	H	(a)	53		273—274	C ₆ H ₅ N ₃ OS ₂	36.5	2.7		36.2	2.5	
OMe	H	H	H	(a)	69	EtOH	192—193 †							
OMe	Me	H	H	(b)	22	Pr ⁱ OH	173—174 ‡							
OMe	Me	Me	H	(b)	25	Pr ⁱ OH	186—187	C ₉ H ₁₁ N ₃ O ₂ S	48.0	5.0	19.1	48.0	4.9	18.7
OMe	CH ₂ ·CO ₂ H	H	H	(b)	28	H ₂ O	230—232	C ₉ H ₉ N ₃ O ₄ S	42.8	3.7	16.5	42.3	3.55	16.4
						Me ₂ N·CHO								
OMe	H	H	Me	(c)	47		125—126	C ₈ H ₉ N ₃ O ₂ S	45.1	4.2	19.7	45.5	4.3	19.9
OMe	H	H	CH ₂ ·CH:CH ₂	(c)	81	Pr ⁱ OH-H ₂ O	64—65	C ₁₀ H ₁₁ N ₃ O ₂ S	49.9	4.9	17.5	50.6	4.7	17.7
OMe	Me	H	Me	(c)	73	Pr ⁱ OH	154—156	C ₉ H ₁₁ N ₃ O ₂ S	47.9	5.1	19.0	48.0	4.9	18.7
OMe	Me	H	CH ₂ ·CH:CH ₂	(c)	48	Pr ⁱ OH-H ₂ O	71—72	C ₁₁ H ₁₃ N ₃ O ₂ S	53.2	5.5	16.8	52.6	5.2	16.7
OMe	Me	Me	Me	(c)	18		123—124	C ₁₀ H ₁₃ N ₃ O ₂ S	50.2	5.5	17.7	50.2	5.5	17.6

* See Experimental section. † Lit.,⁴ 191—193°; E. C. Taylor and E. E. Garcia (*J. Org. Chem.*, 1964, 29, 2121) quote m.p. 190—191°. ‡ Lit.,⁴ 175—176.5.

TABLE 2
¹H N.m.r. data for 4-methoxy-5*H*-pyrimido[4,5-*b*][1,4]thiazin-6(7*H*)-ones^a

Compound (2)				τ Values (J in Hz)					Solvent
X	R ¹	R ²	R ³	2-H	OMe	7-Substituent		5-Substituent	
OMe	H	H	H	1.67	6.05	6.34 (2H, s)		-0.23br (1H, s) ^b	(CD ₃) ₂ SO
OMe	Me	Me	H	1.53	5.88	8.45 (6H, s)		1.73br (1H, s) ^b	CDCl ₃
OMe	CH ₂ ·CO ₂ H	H	H	1.67	6.03	5.89 (1H, t, J 7), 7.18 (2H, d, J 7)		-0.35br (1H, s) ^b	(CD ₃) ₂ SO
OMe	H	H	Me	1.57	5.98	6.34 (2H, s)		6.79 (3H, s)	(CD ₃) ₂ SO
OMe	Me	H	Me	1.54	5.88	6.40 (1H, q, J 7) 8.47 (3H, d, J 7)		6.63 (3H, s)	CDCl ₃
OMe	Me	Me	Me	1.61	5.91	8.54 (6H, s)		6.64 (3H, s)	CDCl ₃
OMe	H	H	CH ₂ ·CH:CH ₂	1.79	6.04	6.64 (2H, s)		5.48 (2H, d, J 6) 4.26—4.64 (1H, m), 4.92—5.10 (2H, m)	CDCl ₃ ^c
OMe	Me	H	CH ₂ ·CH:CH ₂	1.78	6.04	6.55 (1H, q, J 7), 8.53 (3H, d, J 7)		5.23—5.72 (2H, m), 4.24—4.62 (1H, m), 4.92—5.08 (2H, m)	CDCl ₃ ^c
OEt	H	H	H	1.69	d	6.34 (2H)		-0.23br (1H, s) ^b	

^a Measured on a Varian A60A spectrometer at normal probe temperature with tetramethylsilane as internal standard. ^b Removed on deuteration. ^c Measured on a Varian HA-100 spectrometer. ^d Ethoxy-signal τ 5.58 (2H, q, J 7), 8.68 (3H, t, J 7).

acid is known to give the carboxymethylthio-pyrimidothiazinone³ (2; R¹ = R² = R³ = H, X = S·CH₂·CO₂H).

The methoxy-thione (1; X = OMe) was also condensed with bromosuccinic acid, ethyl α-bromopropionate, and ethyl α-bromoisobutyrate to produce the 7-carboxymethyl- (2; X = OMe, R¹ = R³ = H, R² = CH₂·CO₂H), 7-methyl (2; X = OMe, R¹ = R³ = H, R² = Me), and 7,7-dimethyl- (2; X = OMe, R¹ = R² = Me, R³ = H) pyrimidothiazinones (Table 1), identified by ¹H n.m.r. spectroscopy (Table 2) as

³ M. Ishidate and H. Yuki, *Chem. and Pharm. Bull. (Japan)*, 1960, 8, 131.

by acidic hydrolysis. This route was preferred to one in which the first step was hydrolysis of 5-amino-4,6-dichloropyrimidine to 5-amino-6-chloropyrimidin-4(3*H*)-one (4). Treatment of the latter with thio-glycolic acid and related compounds was expected to give pyrimidothiazine-4,6-diones^{4b} but the yield in the first step was too low to make the route practicable.

A range of 5-alkyl-5*H*-pyrimidothiazine-4,6(3*H*,7*H*)-diones (3; R³ = alkyl, R⁴ = H) was obtained by alkylating the 4-methoxy-6(7*H*)-ones (2; X = OMe) with methyl iodide, benzyl chloride, or allyl bromide before

⁴ T. S. Safonova and M. P. Nemeryuk, *Khim. geterotsikh. Soedinenii*, (a) 1966, 5, 714; (b) 1971, 1, 73.

TABLE 3
 5*H*-Pyrimido[4,5-*b*][1,4]thiazine-4,6(3*H*,7*H*)-diones

Compound (3)				Method of prepn.*	Yield (%)	M.p. (°C)	Formula	Found (%)			Required (%)		
R ¹	R ²	R ³	R ⁴					C	H	N	C	H	N
H	CH ₂ ·CO ₂ H	H	H	(d)	66	275—277	C ₈ H ₇ N ₃ O ₄ S	39.5	3.0	17.1	39.8	2.9	17.4
Me	Me	H	H	(d)	42	273	C ₈ H ₉ N ₃ O ₂ S	45.4	4.5	19.8	45.5	4.3	19.9
H	H	Me	H	(d)	53	225—227	C ₇ H ₇ N ₃ O ₂ S	42.4	3.7	21.4	42.6	3.6	21.3
H	H	CH ₂ ·CH·CH ₂	H	(d)	49	146—148	C ₉ H ₉ N ₃ O ₂ S	48.3	4.2	18.8	48.4	4.1	18.8
H	Me	CH ₂ ·CH·CH ₃	H	(d)	55	203—204	C ₁₀ H ₁₁ N ₃ O ₂ S	50.0	4.9	17.4	50.6	4.7	17.7
H	Me	Me	H	(d)	53	250—251	C ₈ H ₉ N ₃ O ₂ S	45.3	4.3	19.5	45.5	4.3	19.9
Me	Me	Me	H	(d)	40	197—199	C ₉ H ₁₁ N ₃ O ₂ S	47.9	5.0	18.7	48.0	4.9	18.7
H	H	CH ₂ ·CH·CH ₂	Me	(e)	45	128—129	C ₁₀ H ₁₁ N ₃ O ₂ S	50.1	4.7	17.7	50.6	4.7	17.7
H	H	Me	Me	(e)	37	239—241	C ₈ H ₉ N ₃ O ₂ S	46.2	4.6	19.8	45.5	4.3	19.9
H	Me	Me	Me	(e)	43	180—181	C ₉ H ₁₁ N ₃ O ₂ S	48.7	5.2	19.3	48.0	4.9	18.7


* See Experimental section.

 TABLE 4
¹H N.m.r. data for 5*H*-pyrimido[4,5-*b*][1,4]thiazine-4,6(3*H*,7*H*)-diones ^a

Compound (3)				τ Values (<i>J</i> in Hz)			Solvent	
R ¹	R ²	R ³	R ⁴	2-H	3-Substituent	5-Substituent		7-Substituents
H	H	Me	H	2.00		6.78 (3H, s)	6.43 (2H, s)	(CD ₃) ₂ SO
Me	Me	H	H	2.01		—0.17br (1H, s) ^b	8.58 (6H, s)	(CD ₃) ₂ SO
Me	Me	Me	H	2.05		6.53 (3H, s)	8.50 (6H, s)	CDCl ₃
Me	H	Me	H	1.98		6.72 (3H, s)	6.20 (1H, q, <i>J</i> 7), 8.63 (3H, d, <i>J</i> 7)	(CD ₃) ₂ SO
Me	H	Me	Me	2.07	6.45 (3H, s)	6.60 (3H, s)	6.30 (1H, q, <i>J</i> 7), 8.48 (3H, d, <i>J</i> 7)	CDCl ₃
H	H	CH ₂ ·CH·CH ₂	H	2.22		5.27 (2H, d, <i>J</i> 6), 4.16—4.53 (1H, m), 4.89—5.06 (2H, m)	6.60 (2H, s)	CDCl ₃ ^c
H	H	CH ₂ ·CH·CH ₂	Me	2.25	6.57 (3H, s)	5.30 (2H, d, <i>J</i> 6), 4.18—4.55 (1H, m), 4.90—5.09 (2H, m)	6.66 (2H, s)	CDCl ₃ ^c
H	CH ₂ ·CO ₂ H	H	H	2.07		0.07 (1H, s) ^b	5.98 (1H, t, <i>J</i> 7), 7.19 (2H, d, <i>J</i> 7)	(CD ₃) ₂ SO

^a Measured on a Varian A60A spectrometer at normal probe temperature with tetramethylsilane as internal standard. ^b Removed on deuteration. ^c Measured on a Varian HA100 spectrometer.

hydrolysis of the 4-methoxy-group. 3,5-Dialkyl derivatives (3; R³ and R⁴ = alkyl) were prepared by



further alkylation of the 5-alkyl compounds (Table 3). Structures of the various alkyl derivatives were confirmed by ¹H n.m.r. spectroscopy (Table 4).

⁵ C. C. Cheng and T. K. Liao, *J. Heterocyclic Chem.*, 1964, **1**, 212.

(c) 5*H*-Pyrimido[4,5-*b*][1,4]thiazine-2,4,6(1*H*,3*H*,7*H*)-triones.—The amino-mercapto-compound (6; R = H), which was derived from the chloro-nitro-compound (5; R = H), was condensed with chloroacetic acid to furnish a 3-methylpyrimidothiazinetrione (7; R = H). The 1,3-dimethyl analogue of the latter was similarly synthesised from 6-chloro-1,3-dimethyl-5-nitropyrimidine-2,4(1*H*,3*H*)-dione (5; R = Me). The last named pyrimidinedione (5; R = Me) has recently been reported by two groups of workers,^{5,6} who (respectively) give its m.p. as 65—68 and 80—83°. It may be obtained more pure (m.p. 85—87°) when prepared under milder nitration conditions than those published. Thus, whereas nitration of the precursor (8; X = Cl, Y = H) with mixed nitric and sulphuric acids at 10—15°, as in ref. 6, gave an impure product, carrying out the reaction at 0—5° gave pure material. Above 15° appreciable hydrolysis to 1,3-dimethyl-5-nitrobarbituric acid (8; X = OH, Y = NO₂) occurred, and some of this was isolated and identified by comparison with an authentic specimen.⁷ When we treated the chloropyrimidine (8; X = Cl, Y = H) with fuming nitric acid and glacial acetic acid at 20—23°, or with nitric acid and acetic anhydride at 0—5°, or with fuming nitric acid alone at 10°, we obtained a different com-

⁶ W. Pfeiderer and E. Bühler, *Chem. Ber.*, 1966, **99**, 2997.

⁷ H. Biltz and K. Sedlatschek, *Ber.*, 1924, **57**, 339.

pound, m.p. 286—287°, which was assigned a 5,6-dihydropyrimidine structure (9). This assignment was based on microanalytical results, the absence of a normal 5-proton signal in the ^1H n.m.r. spectrum, and the mass spectrum. No molecular ion peak was observed but the base peak at m/e 190.0145 (Cl isotope pattern), due to $\text{C}_6\text{H}_7^{35}\text{ClN}_2\text{O}_3$ ions, and another intense peak at m/e 156.0535, due to $\text{C}_6\text{H}_8\text{N}_2\text{O}_3$ ions, may be attributed to reasonable losses of HNO_2 and NO_2Cl , respectively, from the absent molecular ion. The occurrence of addition reactions at the 5,6-bond of pyrimidines, particularly uracil derivatives, is well established and may involve, for example, addition of the elements of nitric acid,^{8,9} hypobromous acid,¹⁰ hypochlorous acid,⁸ or water.¹¹

It has been noted previously² that 4-(substituted-amino-5*H*-pyrimido[4,5-*b*][1,4]thiazin-6(7*H*)-ones (2; X = NHR or NR_2) are acidic, although they are essentially cyclic analogues of acyl derivatives of 4-aminopyrimidines. The present compounds (2; X = OMe, Cl, or OEt) are also freely soluble in sodium hydroxide solution and are reprecipitated on acidification. The 4-methoxy-compound (2; X = OMe, $\text{R}^1 = \text{R}^2 = \text{H}$) and its 7,7-dimethyl derivative (2; X = OMe, $\text{R}^1 = \text{R}^2 = \text{Me}$), for example had pK_a values of 11.00 and 11.28, respectively, and showed very similar spectral changes on ionisation. The fact that the 7,7-dimethyl derivative behaved like the other compounds confirms that it is ionisation of the 5-NH group which is responsible for the acidity of the compounds, and that dissociation of a 7-proton is not involved. Open chain analogues (5-acylamino-pyrimidines) are not appreciably ionised even at pH 14. Perhaps the cyclic anions (10) are more effectively solvated than anions from simple acylamino-groups.

Representative examples of compounds in Tables 1 and 3 showed slight or negligible activity as anti-microbial agents.

EXPERIMENTAL

pK_a Values were measured by a rapid spectrophotometric method.¹² U.v. spectra were recorded on a Unicam SP 800 spectrometer for buffered aqueous solutions. 4-Methoxy-5*H*-pyrimido[4,5-*b*][1,4]thiazin-6(7*H*)-one (pK_a 11.00 \pm 0.02) showed λ_{max} (neutral molecule at pH 8.9) 296 (log ϵ 3.74), 288infr (3.73), and 244 nm (4.21); λ_{max} (anion at pH 13.3) 309infr (3.80), 293 (3.89), and 254 (4.12). Its 7,7-dimethyl derivative (pK_a 11.28 \pm 0.02) showed λ_{max} (neutral molecule at pH 9.0) 292 (log ϵ 3.76), 287infr (3.75), and 243 nm (4.21); λ_{max} (anion at pH 13.3) 311infr (3.82), 293 (3.95), and 253 (4.09).

5-Amino-6-ethoxy-pyrimidine-4(3*H*)-thione.—4-Chloro-6-ethoxy-5-nitropyrimidine (0.8 g) and aqueous *N*-sodium hydrogen sulphide (20 ml) were stirred at 20° until a clear solution was obtained (ca. 45 min), and then at 60—65° for a further 16 h. The solution was acidified with glacial

acetic acid and the resulting solid filtered off and reprecipitated from 0.5*N*-sodium hydroxide (10.8 ml). The ethoxy-pyrimidinethione had m.p. 193—195° (from ethanol) (Found: C, 41.6; H, 5.1; N, 25.1. $\text{C}_6\text{H}_8\text{N}_2\text{OS}$ requires C, 42.1; H, 5.3; N, 25.4%).

5*H*-Pyrimido[4,5-*b*][1,4]thiazin-6(7*H*)-ones.—(a) 4-Substituted derivatives. The appropriate aminopyrimidinethione (1 equiv.), chloroacetic acid (1.1 equiv.) and *N*-sodium hydroxide solution (2.2 equiv.) were heated at 90—95° for 1 h. The cooled solution was adjusted to pH 1 with 5*N*-hydrochloric acid and the pure pyrimidothiazinone (2; $\text{R}^1 = \text{R}^2 = \text{H}$) was filtered off (Table 1).

(b) 7-Substituted 4-methoxy-derivatives. 5-Amino-6-methoxy-pyrimidine-4(3*H*)-thione (1.57 g), *N*-sodium hydroxide (12 ml), and ethyl α -bromopropionate (1.54 ml) were shaken together vigorously for 5 min before being heated at 90—95° for 1 h. The 7-methyl compound (0.46 g) separated from the cooled solution (Table 1). The same pyrimidine (1.1 g), *N*-sodium hydroxide solution (8.4 ml), and ethyl α -bromoisobutyrate (1.23 ml) were similarly condensed together, but for 3 h, to yield the 7,7-dimethyl derivative (0.37 g) (Table 1). The pyrimidine (0.63 g), *N*-sodium hydroxide (8.8 ml), and bromosuccinic acid (0.94 g) were heated at 90—95° for 1 h. The cooled solution, on acidification to pH 1 with 5*N*-hydrochloric acid, yielded the 7-carboxymethyl derivative (0.37 g) (Table 1).

(c) 5-Alkyl-4-methoxy-derivatives. The appropriate thiazinone (1 equiv.), methyl iodide (or allyl bromide) (1.1 equiv.), and *N*-sodium hydroxide (1.1 equiv.) were shaken for a suitable time (24—48 h). The products were filtered off and washed with a little water (methyl derivatives) or propan-2-ol (allyl derivatives) before recrystallisation from a suitable solvent (Table 1).

5*H*-Pyrimido[4,5-*b*][1,4]thiazin-4,6(3*H*,7*H*)-diones.—(d) 3-Unsubstituted derivatives. The 4-methoxy-pyrimidothiazinone (2; X = OMe) (0.3 g) and 2*N*-hydrochloric acid (3 ml) were stirred under reflux until a clear solution was obtained and for a further 2 h. The product crystallised from the cooled solution in an analytically pure state (Table 3).

(e) 3,5-Dialkyl derivatives. The relevant 5-alkyl compound (0.4 g) in 0.5*N*-sodium hydroxide (4.8 ml) was vigorously shaken with methyl iodide (0.15 ml) for 24—36 h. The product was filtered off and crystallised from a suitable solvent (Table 3).

5-Amino-6-chloropyrimidin-4(3*H*)-one.—A mixture of 5-amino-4,6-dichloropyrimidine (1.63 g) and 6*N*-hydrochloric acid (15 ml) was heated under reflux for 1 h and evaporated to dryness under reduced pressure. The residue was suspended in water (3 ml) and pH adjusted to 4 with *N*-sodium hydroxide. The pyrimidone was filtered off and crystallised from water as buff crystals (0.6 g), m.p. 241° (Found: C, 33.2; H, 2.8; N, 29.1. $\text{C}_4\text{H}_4\text{ClN}_3\text{O}$ requires C, 33.0; H, 2.8; N, 28.9%).

5-Amino-6-mercapto-3-methylpyrimidine-2,4(1*H*,3*H*)-dione (6; R = H).—6-Chloro-3-methyl-5-nitropyrimidine-2,4(1*H*,3*H*)-dione (3.6 g) was heated under reflux for 3 h with a solution of sodium hydrogen sulphide prepared by saturating 2*N*-sodium hydroxide (53 ml) with hydrogen sulphide. The solution was acidified with glacial acetic acid and filtered. The mercapto-compound, purified by

⁸ T. B. Johnson, *Amer. Chem. J.*, 1908, **40**, 19.

⁹ T. B. Johnson, *J. Biol. Chem.*, 1908, **4**, 407.

¹⁰ O. Baudisch and D. Davidson, *Ber.*, 1925, **58**, 1680; *J. Biol. Chem.*, 1925, **64**, 234; S. Y. Wong, *J. Org. Chem.*, 1959, **24**, 11; J. R. Piper and T. P. Johnston, *ibid.*, 1965, **30**, 1247.

¹¹ A. M. Moore, *Canad. J. Chem.*, 1958, **36**, 281; A. M. Moore and C. H. Thompson, *ibid.*, 1957, **35**, 163; *Science*, 1955, **122**, 594.

¹² J. Clark and A. E. Cunliffe, *Chem. and Ind.*, 1973, 281.

reprecipitation from 2*N*-sodium hydroxide after alkali-insoluble matter had been filtered off, had m.p. >300° (Found: C, 34.0; H, 3.7; N, 23.7. C₅H₇N₃O₂S requires C, 34.7; H, 4.1; N, 24.3%).

3-Methyl-5H-pyrimido[4,5-b][1,4]thiazine-2,4,6(1H,3H,7H)-trione (7; R = H).—The foregoing mercapto-compound (0.5 g) and chloroacetic acid (1.5 g) were heated at 140° for 5 min and cooled. The excess of chloroacetic acid was extracted with water (20 ml) and the residue boiled with dimethylformamide (20 ml). The insoluble *pyrimidothiazinetrione* (0.2 g), m.p. >300°, was filtered off as a buff solid (Found: C, 39.4; H, 3.4; N, 19.7. C₇H₇N₃O₃S requires C, 39.4; H, 3.3; N, 19.7%).

6-Chloro-1,3-dimethyl-5-nitro-uracil.—6-Chloro-1,3-dimethyluracil (8.5 g) was added in portions to stirred concentrated sulphuric acid (25 ml), kept below 15° by cooling in ice. Fuming nitric acid (8.4 ml) was added slowly, the temperature being maintained at 0–5°, and the solution was then poured onto ice (100 g) with stirring. The product was at once extracted into chloroform (2 × 100 ml) and the extract was dried (MgSO₄) and quickly evaporated to afford a yellow crystalline solid (5.4 g), m.p. 85–87° (lit.,^{4b} 65–68°; lit.,⁵ 80–83°).

1,3-Dimethyl-5H-pyrimido[4,5-b][1,4]thiazine-2,4,6(1H,3H,7H)-trione.—The foregoing chloro-compound (3.29 g) and aqueous 2*N*-sodium hydrogen sulphide solution (38 ml) were stirred under reflux for 3 h, acidified with glacial acetic acid, and filtered. The solid was reprecipitated from 2*N*-sodium hydroxide after removal of alkali-insoluble matter and heated with chloroacetic acid (0.69 g) and 0.5*N*-sodium hydroxide (14.5 ml) at 90–95° for 1 h. The *pyrimidothiazinetrione* (0.42 g), m.p. 250°, separated from the cooled solution (Found: C, 41.8; H, 3.8; N, 18.1. C₈H₉N₃O₃S requires C, 42.3; H, 4.0; N, 18.5%).

A solution of the compound (0.38 g) in *n*-sodium hydroxide (2 ml) gradually deposited the sodium salt (0.27 g).

5-Benzyl-1,3-dimethyl-5H-pyrimido[4,5-b][1,4]thiazine-2,4,6(1H,3H,7H)-trione.—The foregoing sodium salt (0.27

g), water (3 ml), ethanol (3 ml), and benzyl chloride (0.15 ml) were heated under reflux for 1 h and evaporated to dryness under reduced pressure. Water (2 ml) was added to the residue and the *benzyl derivative* (0.062 g), m.p. 181–182° (from aqueous ethanol), was filtered off (Found: C, 55.8; H, 4.8; N, 13.5. C₁₅H₁₅N₃O₃S requires C, 56.8; 4.8; N, 13.2%).

6-Chloro-5,6-dihydro-1,3-dimethyl-6-hydroxy-5-nitro-uracil (9).—(a) 6-Chloro-1,3-dimethyluracil (10.5 g) was added in portions to a stirred mixture of glacial acetic acid (21.6 ml) and fuming nitric acid (7.8 ml) maintained at 20–23°. The solution was stirred for a further 0.5 h, then poured onto ice, evaporated to small bulk, cooled, and treated with water (60 ml). The *hydroxy-nitro-compound* (5.1 g) which separated had m.p. 286–287° [from light petroleum (b.p. 80–100°) or methanol] (Found: C, 30.8; H, 2.9; N, 17.6. C₈H₈ClN₃O₅ requires C, 30.3; H, 3.4; N, 17.7%).

(b) 6-Chloro-1,3-dimethyluracil (1.75 g) was added in portions during 15 min to stirred fuming nitric acid (5 ml) kept at 10°. The solution was stirred at 20° for a further 0.5 h, then poured onto ice, and the product (1.1 g), m.p. 286–287° (from ethanol), was isolated as in (a).

(c) The same product was obtained by treating 6-chloro-1,3-dimethyluracil (1.75 g) in acetic anhydride (8 ml) at 0° with a mixture of fuming nitric acid (1.3 ml) and acetic anhydride (8 ml). After 0.5 h at 0–5° and 0.5 h at 20° the mixture was poured onto ice and treated as in (a) [yield 0.76 g; m.p. 286–187° (from methanol)].

We thank the S.R.C. for a Co-operative Award in Pure Science (to I. W. S.) and Messrs Allen and Hanburys Ltd., who co-operated in the work and carried out the pharmaceutical testing. We also thank Mr. A. E. Cunliffe for p*K*_a values and u.v. spectra, Mrs. R. Maynard for mass spectra, and Mr. D. J. Barraclough for n.m.r. spectra.

[4/353 Received, 22nd February, 1974]